Nearly all implantable bioelectronics are powered by bulky batteries
which limit device miniaturization and lifespan. Moreover, batteries contain
toxic materials and electrolytes that can be dangerous if leakage occurs.
Herein, an approach to fabricate implantable protein-based bioelectrochemical
capacitors (bECs) employing new nanocomposite heterostructures in which 2D
reduced graphene oxide sheets are interlayered with chemically modified
mammalian proteins, while utilizing biological fluids as electrolytes is
described. This protein-modified reduced graphene oxide nanocomposite material
shows no toxicity to mouse embryo fibroblasts and COS-7 cell cultures at a high
concentration of 1600 μg mL−1 which is 160 times
higher than those used in bECs, unlike the unmodified graphene oxide which
caused toxic cell damage even at low doses of 10 μg
mL−1. The bEC devices are 1 μm thick, fully
flexible, and have high energy density comparable to that of lithium thin film
batteries. COS-7 cell culture is not affected by long-term exposure to
encapsulated bECs over 4 d of continuous charge/discharge cycles. These bECs are
unique, protein-based devices, use serum as electrolyte, and have the potential
to power a new generation of long-life, miniaturized implantable devices.